Get the Stockscreener App
27.49
5.17%
-1.50
Pre-market:
27.48
-0.010
-0.04%
Apellis Pharmaceuticals Inc stock is traded at $27.49, with a volume of 3.36M.
It is down -5.17% in the last 24 hours and down -1.82% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
See More
Previous Close:
$28.99
Open:
$28.78
24h Volume:
3.36M
Relative Volume:
1.24
Market Cap:
$3.45B
Revenue:
$715.22M
Net Income/Loss:
$-250.10M
P/E Ratio:
-5.2362
EPS:
-5.25
Net Cash Flow:
$-205.58M
1W Performance:
-2.69%
1M Performance:
-1.82%
6M Performance:
-36.40%
1Y Performance:
-44.46%
1-Day Range:
$27.38
$28.98
1-Week Range:
$25.76
$30.80
52-Week Range:
$24.34
$73.80
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| APLS | 27.49 | 3.45B | 715.22M | -250.10M | -205.58M | -5.25 |
| VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Victory Capital Management Inc. Sells 49,960 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y - MSN
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback - Investing.com India
Apellis Pharmaceuticals shares surge following Astellas Pharma’s FDA setback By Investing.com - Investing.com Canada
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap UpHere's What Happened - MarketBeat
Apellis reiterates neutral rating, steady stock target on FDA decision By Investing.com - Investing.com UK
GSA Capital Partners LLP Purchases New Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
T. Rowe Price Investment Management Reduces Stake in Apellis Pha - GuruFocus.com
Apellis Pharmaceuticals to Present at Jefferies London Healthcare Conference 2024 | APLS Stock News - StockTitan
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference - The Manila Times
(APLS) Trading Signals - Stock Traders Daily
Fiera Capital Corp Lowers Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Wellington Management Group LLP Reduces Stake in Apellis Pharmac - GuruFocus.com
HC Wainwright Has Negative Outlook of APLS FY2024 Earnings - MarketBeat
William Blair Issues Pessimistic Forecast for APLS Earnings - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript - MSN
Robert W. Baird Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Wedbush Cuts Earnings Estimates for Apellis Pharmaceuticals - MarketBeat
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise By Investing.com - Investing.com Nigeria
Earnings call: Apellis Pharmaceuticals Q3 2024 results show promise - Investing.com
Wells Fargo & Company Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $30.00 - MarketBeat
Old West Investment Management LLC Purchases Shares of 102,403 Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Oppenheimer Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $40.00 - MarketBeat
Needham & Company LLC Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $60.00 - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $57.00 by Analysts at HC Wainwright - MarketBeat
Bank of America Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $47.00 - MarketBeat
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Lags Revenue Estimates - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $32.00 by Analysts at Piper Sandler - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlig - GuruFocus.com
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Apellis Pharmaceuticals (APLS) Stock Moves After Q3 Results - GuruFocus.com
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results - citybiz
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday - MSN
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Hits New 52-Week LowShould You Sell? - MarketBeat
Apellis Pharma stock hits 52-week low at $25.31 amid market challenges - Investing.com Canada
Apellis Pharmaceuticals (APLS) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Apellis stock drops after Q3 miss (APLS:NASDAQ) - Seeking Alpha
47,500 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Bought by AlphaCentric Advisors LLC - MarketBeat
Apellis Q3 Revenue Soars to $196.8M, SYFOVRE Growth Continues Despite Price Adjustments | APLS Stock News - StockTitan
Apellis Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Will Apellis Pharmaceuticals, Inc. (APLS) Report Negative Earnings Next Week? What You Should Know - MSN
A Glimpse of Apellis Pharmaceuticals's Earnings Potential - Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals - Benzinga
Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Sector Perform" Rating from Royal Bank of Canada - MarketBeat
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Previ - GuruFocus.com
Apellis Pharmaceuticals Inc (APLS) Q3 2024 Earnings Report Preview: What to Look For - Yahoo Finance
Allspring Global Investments Holdings LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Rating Increased to Strong-Buy at Evercore ISI - MarketBeat
Analysts Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $65.41 - MarketBeat
What is William Blair's Forecast for APLS Q1 Earnings? - MarketBeat
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
6.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):